Switzerland-based cancer specialist Helsinn Group on Monday said the European Medicines Agency has agreed to review marketing authorization application (MAA) for its anamorelin HCI, to treat anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.
Riccardo Braglia, chief executive of Helsinn Group, said: “With this EMA submission, we are one step closer to bringing this new and potentially effective treatment to market, meaning that the quality of life for patients with non-small cell lung cancer who suffer from anorexia, cachexia, could soon improve. Anamorelin is part of our pipeline of products dedicated to cancer supportive care, all of which address areas of significant unmet medical need.”
Anamorelin HCI is an orally active ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in NSCLC patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze